Superiority of the DNA Amplification Assay for the Diagnosis of C. difficile Infection: A Clinical Comparison of Fecal Tests
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Clostridium difficile infection (CDI) is a major infectious concern, accounting for substantial morbidity and resource utilization. Advances in microbiological and molecular techniques have resulted in an increasing number of testing options for CDI. A glutamate dehydrogenase (GDH) enzyme immunoassay (EIA) and a DNA amplification (DNA-A) test for the diagnosis of CDI have recently become commercially available.
The aim of this prospective study was to compare the test performance characteristics of the traditional diagnostic modality for CDI diagnosis, the toxin A/B (TOX) EIA, with those of the GDH EIA and DNA-A test, utilizing enriched toxigenic culture (TGC) as the gold standard. Clinical variables predictive of CDI were also studied.
Participants fulfilled one or more criteria placing them at increased risk for CDI. Each stool sample was tested by each of the methods mentioned above. Clinical data parameters were collected via a 12-month review of the electronic medical record prior to the index date of the first stool test.
A total of 272 stool samples from 144 admissions of 139 patients were evaluated for CDI. The sensitivity and positive predictive value (PPV) of the TOX EIA were 86.1 and 58.4 %, respectively, whereas the sensitivity and PPV of the GDH EIA and DNA-A test were 100 %. 1.8 % of the GDH tests yielded inconclusive results. Using TGC as the gold standard, nosocomial exposure with emphasis on nursing home residence, history of previous CDI, and female gender were predictive of CDI.
Test performance characteristics of the DNA-A test and GDH EIA were superior to those of the traditional TOX EIA. The GDH test is limited by inconclusive test results and requires a multi-step diagnostic algorithm. Therefore, the DNA-A test should be implemented as the diagnostic method of choice for CDI. CDI clinical predictors are important for diagnostic decision-making.
- Superiority of the DNA Amplification Assay for the Diagnosis of C. difficile Infection: A Clinical Comparison of Fecal Tests
Digestive Diseases and Sciences
Volume 57, Issue 10 , pp 2592-2599
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- Clostridium difficile
- Immunoenzyme assays
- DNA amplification
- Industry Sectors
- Author Affiliations
- 1. Division of Gastroenterology, Department of Medicine, University of Miami Miller School of Medicine, P.O. Box 016960 (D49), Miami, FL, 33101-6960, USA
- 2. Department of Pathology, Mount Sinai Medical Center, 4300 Alton Road, Miami Beach, FL, 33140, USA
- 3. Department of Medicine, Mount Sinai Medical Center, 4300 Alton Road, Miami Beach, FL, 33140, USA